Prestige Brands Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tarrytown NY United States (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
2017
NCT03013504
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Prestige Biopharma Limited | Prestige Biopharma Ltd | Prestige Biopharma Pte Ltd

Active Ingredients

Drugs in Phase 3 Trials (5)

bevacizumab (avastin) (2 trials)

carboplatin (paraplatin) (1 trial)

docetaxel (taxotere) (1 trial)

paclitaxel (taxol) (1 trial)

trastuzumab (herceptin) (2 trials)

Drugs in Phase 2 Trials (3)

Key: Prestige Brands (2) Acquired (1)

fm-601 (2 trials)

gemcitabine (gemzar) (1 trial)

pbp1510 (1 trial)

Drugs in Phase 1 Trials (1)

adalimumab (humira) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 9